: iStockAnalyst.com Symbols Feed

Vicor Technologies Issued Australian Patent for Its Altered State Physiology Drug Development Platform

Tue, 29 Sep 2009 13:50:00 GMT

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform.
Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i(R) nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.
This platform may be used to advance the treatment of an array of human conditions, including stroke ischemia, cardiac ischemia, kidney failure, hypertension, obesity, cancer, and organ transplant/preservation, by reducing the cost, time, and risk associated with bringing related pharmaceuticals to market.

Original Research Using Vicor Technologies' PD2i Algorithm Published in Therapeutics and Clinical Risk Management

Tue, 25 Aug 2009 12:25:00 GMT

BOCA RATON, FL -- -- 08/25/09 -- David H. Fater, CEO of Vicor Technologies, Inc. , today announced that original research conducted using its PD2i algorithm to prospectively predict risk of sudden cardiac death was published in Therapeutics and Clinical Risk Management . Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of life saving intervention.[More...]

Vicor Technologies Announces International Distribution Agreement; Revenues Expected to Commence in 4Q09

Wed, 19 Aug 2009 13:52:00 GMT

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that the Company has entered into an exclusive distributorship agreement with Glotecx, Inc. for the distribution of its PD2i Cardiac Analyzer.
Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i algorithm and software to stratify patients at risk of sudden cardiac death (SCD) and trauma victims in need of life saving intervention.
The agreement grants Glotecx the exclusive right to purchase, inventory, promote, and resell the private label Vicor PD2i Cardiac Analyzer, and accompanying computer hardware and test analyses in India, Kenya, Uganda, Tanzania, and Nigeria.

: iStockAnalyst.com Symbols Feed

Vicor Technologies Issued Australian Patent for Its Altered State Physiology Drug Development Platform

Original Research Using Vicor Technologies' PD2i Algorithm Published in Therapeutics and Clinical Risk Management

Vicor Technologies Announces International Distribution Agreement; Revenues Expected to Commence in 4Q09

Vista Partners Initiates Coverage on Vicor Technologies, Inc. (OTCBB: VCRT) With $2.96 Price Target

Trial Findings for Vicor Technologies PD2i Vital Sign Diagnostic to Be Presented at the ATACCC 2009 Conference

Vicor Technologies Announces Sale of Convertible Notes

Vicor Technologies Announces OEM Agreement

/ CORRECTION - Vicor Technologies CEO Discusses New Developments With CEOCFO

Vicor Technologies CEO Discusses New Developments With CEOCFO

Vicor Technologies Retains Cameron Associates for Investor Relations Services

Form 4 Weiss Daniel N For: Oct 30 (10K)

Form 4 Fater David H For: Oct 30 (10K)

Form 4 Weiss Daniel N For: Oct 02 (10K)

Form 4 Fater David H For: Oct 01 (10K)

Form 4 Weiss Daniel N For: Aug 31 (10K)

Form 4 Fater David H For: Sep 01 (10K)

Form 4 Franchetti Joseph A. For: Aug 18 (10K)

Form 4 Hudson Frederick M. For: Aug 18 (10K)

Form 4 Wiesmeier Edward For: Aug 18 (10K)

Form 4/A Vicor Technologies, Inc. For: Jun 30 (10K)